Biotech Start-Up Talking20 to Provide DTC Proteomic and Metabolomic Testing | GenomeWeb

While the last decade saw the rise – and sometimes fall – of a number of direct-to-consumer genomics firms, including 23andMe, Navigenics, and Decode Genetics, the market for DTC proteomics has remained largely unexplored.

A new DTC proteomics and metabolomics firm hopes to change that. San Francisco-based Talking20 launched two weeks ago at the Open Science Summit in Mountain View, Calif. Since then the company has sold several hundred kits to interested users, founder and CEO Heather Heine told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.